Biopharma | Kendall Square

Open Innovation Event Webinar

10:00 – 10:15 AM | Opening by Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies 10:15 – 10:45 AM | Real Time Metabolomics in Biotechnology and Biopharma | Karl Burgess, Senior Lecturer...

1:00 AM 5:00 AM – 5:00 AM
9:00 AM

Future of (how we) Work Task Force

Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

8:00 AM 1:00 PM – 9:30 AM
2:30 PM

The ‘Invisible’ Future of Health Monitoring

If the current pandemic has taught us anything, it is the importance of monitoring not only our own health but the health of our loved ones. It has reiterated the...

6:00 AM 11:00 AM – 7:30 AM
12:30 PM

Future of (how we) Work Task Force

Business of Biotech 201: From Molecule to Market, R&D and Regulatory Considerations

Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...

10:00 AM 2:00 PM – 12:30 PM
4:30 PM

Business of Biotech 201: From Molecule to Market, R&D and Regulatory Considerations

Future of (how we) Work Task Force

Registration for MALSI+ 2021 is open

Don’t miss the Commonwealth’s flagship event connecting scientific innovators, entrepreneurs, business leaders, and investors to celebrate the many ways Massachusetts leads the nation in bringing translational science to the market!...

4:30 AM 8:30 AM – 10:30 AM
2:30 PM

Future of (how we) Work Task Force

The Genetics of Opioid Addiction: What We Know, What We Are Learning

The opioid epidemic is a pressing public health crisis. Opioid overdoses have become the leading cause of accidental death, surpassing automobile accidents. This crisis has only been exacerbated during the...

11:00 AM 3:00 PM – 12:00 PM
4:00 PM

Future of (how we) Work Task Force

Global Cooperation on Medical Advancements: Collaborating between Japan and the US

In an increasingly global society, collaboration and knowledge-sharing between countries offer opportunities for expedited and cost-effective advancements in the medical and biotech fields. At the same time, creating global devices...

11:00 AM 4:00 PM – 2:30 PM
7:30 PM

Biopharma

Biogen to make experimental ALS drug available to dying patients

The new mRNA vaccines from Pfizer and Moderna to fight the coronavirus are based on a technology that could transform the future of medicine.

Biopharma

Biological sensors developed by Glympse Bio, a startup that spun out of the lab of MIT Professor Sangeeta Bhatia, could help clinicians make decisions for individual patients.

Biopharma

Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the commercial rights to a Sage Therapeutics’ oral depression drug, zuranolone.

Last week, Anne Heatherington, Ph.D., senior vice president and head of Data Sciences Institute at Takeda shared that competitive barriers that typically limit the sharing of data have been broken down during the global response.

Biopharma

Johnson & Johnson entered its final stage of clinical trials for its COVID-19 vaccine. What differentiates their vaccine candidate from others is that it does not need to be frozen and may require just one injection.

Nine CEOs signed a pledge outlining a united commitment to sustain the integrity of the scientific process as they work toward potential regulatory filings and approvals of the first COVID-19 vaccines.

Bayer has entered a collaboration agreement with Recursion Pharmaceuticals to strengthen AI-guided drug discovery and advance new treatments for fibrotic diseases of the lung, kidney, heart, and more.

Biopharma

Moderna CEO sees ‘high probability’ of success with Covid-19 vaccine

Recent history suggests a new vaccine entering human clinical trials has about a 1-in-3 chance of getting FDA approval. Stephane Bancel, chief executive of Moderna, pegs the chances of his company’s novel coronavirus vaccine at closer to 80% to 90%.